BioAge Labs, Inc. (BIOA)
| Market Cap | 234.07M +7.9% |
| Revenue (ttm) | 10.36M +168.1% |
| Net Income | -94.46M |
| EPS | -2.37 |
| Shares Out | 45.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 456,729 |
| Open | 5.48 |
| Previous Close | 5.53 |
| Day's Range | 5.05 - 5.48 |
| 52-Week Range | 4.81 - 25.96 |
| Beta | 1.08 |
| Analysts | Buy |
| Price Target | 32.56 (+538.43%) |
| Est. Earnings | Nov 5, 2026 |
About BIOA
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for BIOA stock is "Buy." The 12-month stock price target is $32.56, which is an increase of 538.43% from the latest price.
News
Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapies Partnership applies Deep Or...
BioAge Labs initiated with a Neutral at UBS
UBS analyst Alice Nettleton initiated coverage of BioAge Labs (BIOA) with a Neutral rating and $8 price target While the company’s lead asset BGE-102 would be a differentiated NLRP3 inhibitor,…
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for ...
BioAge Labs Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
BGE-102, a novel NLRP3 inhibitor, is advancing through two phase II trials targeting cardiometabolic and ophthalmology indications, with strong early efficacy and safety data. Strategic collaborations, a robust platform, and a broad IP estate support pipeline growth, while the ASCVD program is paused pending external data.
BioAge Labs Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
BGE-102, a best-in-class NLRP3 inhibitor, is advancing in phase II trials for cardiovascular and retinal diseases, with key efficacy data expected next year. The pipeline also includes an apelin agonist nearing IND filing and strong strategic partnerships. Cash reserves support operations into 2029.
BioAge Labs Transcript: Citigroup’s Biopharma Back to School Summit 2026
BGE-102 advanced to two phase II trials, including DME, with strong biomarker and safety data. The oral therapy's unique profile targets unmet needs in ophthalmology and metabolic diseases, while robust financials and a data-driven pipeline support expansion into new indications.
BioAge Labs doses first patient in QUELL-DME study
BioAge Labs (BIOA) announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102 in adults with diabetic macular edema. Th...
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity a...
BioAge Labs price target lowered to $20 from $23 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on BioAge Labs (BIOA) to $20 from $23 and keeps an Equal Weight rating on the shares.
BioAge Labs price target lowered to $21 from $52 at Citi
Citi lowered the firm’s price target on BioAge Labs (BIOA) to $21 from $52 and keeps a Buy rating on the shares.
BioAge Labs reports Q2 EPS (58c), consensus (62c)
Reports Q2 revenue $2.45M, consensus $1.5M. “NLRP3 sits at the apex of the inflammatory cascade that drives a range of diseases,” said Kristen Fortney, CEO and co-founder of BioAge. “Our…
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026
BioAge Labs Quarterly report: Q2 2026
BioAge Labs has published its Q2 2026 quarterly earnings report on August 5, 2026.
BioAge Labs Earnings release: Q2 2026
BioAge Labs released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
BioAge Labs price target lowered to $25 from $36 at Roth Capital
Roth Capital analyst Adam Walsh lowered the firm’s price target on BioAge Labs (BIOA) to $25 from $36 and keeps a Buy rating on the shares after Novo Nordisk’s (NVO)…
BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi
Citi notes that BioAge Labs (BIOA) shares are down greater than 60% following the news that Novo Nordisk’s (NVO) ZEUS trial for ziltivekimab failed to demonstrate a benefit on MACE.
BioAge Labs price target lowered at Jefferies after Novo trial miss
Jefferies lowered the firm’s price target on BioAge Labs (BIOA) to $21 from $62 and keeps a Buy rating on the shares, stating that the “outright MACE failure” of Novo…
BioAge Labs price target lowered to $50 from $60 at Oppenheimer
Oppenheimer lowered the firm’s price target on BioAge Labs (BIOA) to $50 from $60 and keeps an Outperform rating on the shares.
BioAge Labs doses first participant in QUELL-CV trial of BGE-102
BioAge Labs (BIOA) announced that the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetran...
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular ris...
BioAge Labs Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Lead oral NLRP3 inhibitor BGE-102 showed strong phase I efficacy and safety, with phase II cardiovascular data expected by year-end and ophthalmology results mid-next year. APJ agonists and collaborations with Novartis and Lilly expand the pipeline, supported by $385M cash runway into 2026.
BioAge Labs Transcript: Jefferies Global Healthcare Conference 2026
BGE-102, a novel NLRP3 inhibitor, showed strong biomarker reductions and excellent tolerability in phase I, with phase II cardiovascular and DME trials underway. The program is well-funded, with key data and potential phase III enablement expected by year-end.
BioAge Labs initiated with a Buy at Roth Capital
Roth Capital analyst Adam Walsh initiated coverage of BioAge Labs (BIOA) with a Buy rating and $36 price target The firm believes the company’s lead asset BGE-102, am NLRP3 program…
BioAge Labs initiated with a Buy at BTIG
BTIG initiated coverage of BioAge Labs (BIOA) with a Buy rating and $40 price target BioAge is a clinical-stage biopharmaceutical company focused on treating disease related to human aging, the…
BioAge Labs Transcript: R&D Day 2026
BGE-102, an oral NLRP3 inhibitor, showed robust Phase I efficacy and safety, with up to 86% CRP reduction and strong CNS/retinal penetration. Phase II trials in cardiovascular risk and diabetic macular edema are underway, supported by a strong cash position and expert validation of the anti-inflammatory strategy.